Autoimmune therapy
AssigneeLDN Pharma Limited
InventorsWai Liu, Angus Dalgleish
Life of this patent
Estimating the term…
Abstract
The present invention relates to naltrexone or an analogue thereof, wherein the analogue is methylnaltrexone, naloxone, nalmefene and nalorphine and vitamin D or an active metabolite, or a pharmaceutically acceptable salt of either for separate, sequential or simultaneous administration, for use in the therapy of an autoimmune disease.
Claims5
A method of treating an autoimmune disease comprising administering simultaneously naltrexone or a pharmaceutically acceptable salt thereof, and vitamin D or a pharmaceutically acceptable salt thereof, wherein the autoimmune disease is psoriasis, Systemic Lupus Erythematosus (SLE) or thyroiditis, wherein the naltrexone or pharmaceutically acceptable salt thereof is administered at a dose less than 0.5 mg/kg.
A method for the treatment of an autoimmune disease, comprising administering a subject in need thereof, a therapeutically effective amount of naltrexone or a pharmaceutically acceptable salt thereof, and vitamin D or a pharmaceutically acceptable salt thereof, wherein said naltrexone or pharmaceutically acceptable salt thereof and said vitamin D or pharmaceutically acceptable salt thereof are administered simultaneously, wherein the autoimmune disease is psoriasis, Systemic Lupus Erythematosus (SLE) or thyroiditis, wherein the naltrexone or pharmaceutically acceptable salt thereof is administered at a dose less than 0.5 mg/kg.
Dependencies are inferred from the claim text.